文献速递糖尿病

识别2型糖尿病亚组对指导强化治疗的潜在价值:数据驱动聚类与风险驱动亚组的比较

Potential Value of Identifying Type 2 Diabetes Subgroups for Guiding Intensive Treatment: A Comparison of Novel Data-Driven Clustering With Risk-Driven Subgroups.
PubMed 文献 · Diabetes Care · 2023-01-01

研究将Hoorn糖尿病关怀系统队列中2935例新诊断2型糖尿病患者分别按RHAPSODY数据驱动聚类分为5个亚组、按指南固定切点分为4个风险驱动亚组,用UKPDS Outcomes Model 2估算终身并发症成本与质量调整生命年(QALYs)。风险驱动亚组对预后区分更好,两种分层方法均支持分层强化治疗,风险驱动亚组在识别最可能从强化治疗中获益者方面略优。

要点

  • 风险驱动亚组较数据驱动聚类对预后区分更好。
  • 在HbA1c之外针对BMI和LDL治疗,QALYs增益最高可达10倍。
  • 高 riesgo 亚组治疗费用可分别增加22.0%(数据驱动)和25.3%(风险驱动)仍具成本效果。

核心结论

  • 风险驱动亚组对预后区分更好,两种分层方法均支持分层强化治疗,风险驱动亚组在识别最可能从强化治疗中获益者方面略优。
  • 无论采用何种分层方法,更好的胆固醇和体重控制均显示出可观的健康获益潜力。

研究设计与样本

  • 研究纳入Hoorn糖尿病关怀系统(DCS)队列中2935例新诊断2型糖尿病患者。
  • 按RHAPSODY数据驱动聚类(基于年龄、BMI、HbA1c、C肽和HDL)分为5个亚组,并按指南固定HbA1c和心血管疾病风险切点分为4个风险驱动亚组。
  • 采用UK Prospective Diabetes Study Outcomes Model 2估算各亚组及全部个体的贴现预期终身并发症成本和QALYs,并与DCS观察到的常规护理比较强化治疗增益。
  • 基于Ahlqvist亚组进行敏感性分析。

主要发现

  • 常规护理下,RHAPSODY数据驱动亚组的预后范围为7.9至12.6 QALYs。
  • 风险驱动亚组的预后范围为6.8至12.0 QALYs。
  • 与同质性2型糖尿病相比,高危亚组个体治疗费用可分别增加22.0%(数据驱动亚组)和25.3%(风险驱动亚组)仍具成本效果。
  • 在HbA1c之外针对BMI和LDL治疗,QALYs增益最高可达10倍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the impact on lifetime health and economic outcomes of different methods of stratifying individuals with type 2 diabetes, followed by guideline-based treatment intensification targeting BMI and LDL in addition to HbA1c. RESEARCH DESIGN AND METHODS: We divided 2,935 newly diagnosed individuals from the Hoorn Diabetes Care System (DCS) cohort into five Risk Assessment and Progression of Diabetes (RHAPSODY) data-driven clustering subgroups (based on age, BMI, HbA1c, C-peptide, and HDL) and four risk-driven subgroups by using fixed cutoffs for HbA1c and risk of cardiovascular disease based on guidelines. The UK Prospective Diabetes Study Outcomes Model 2 estimated discounted expected lifetime complication costs and quality-adjusted life-years (QALYs) for each subgroup and across all individuals. Gains from treatment intensification were compared with care as usual as observed in DCS. A sensitivity analysis was conducted based on Ahlqvist subgroups. RESULTS: Under care as usual, prognosis in the RHAPSODY data-driven subgroups ranged from 7.9 to 12.6 QALYs. Prognosis in the risk-driven subgroups ranged from 6.8 to 12.0 QALYs. Compared with homogenous type 2 diabetes, treatment for individuals in the high-risk subgroups could cost 22.0% and 25.3% more and still be cost effective for data-driven and risk-driven subgroups, respectively. Targeting BMI and LDL in addition to HbA1c might deliver up to 10-fold increases in QALYs gained. CONCLUSIONS: Risk-driven subgroups better discriminated prognosis. Both stratification methods supported stratified treatment intensification, with the risk-driven subgroups being somewhat better in identifying individuals with the most potential to benefit from intensive treatment. Irrespective of stratification approach, better cholesterol and weight control showed substantial potential for health gains.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Li X, van Giessen A, Altunkaya J, et al. Potential Value of Identifying Type 2 Diabetes Subgroups for Guiding Intensive Treatment: A Comparison of Novel Data-Driven Clustering With Risk-Driven Subgroups. Diabetes Care. 2023. PMID: 37146005. doi:10.2337/dc22-2170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。